Navigation Links
Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS
Date:10/15/2007

PITTSBURGH, Oct. 15 /PRNewswire/ -- Knopp Neurosciences Inc. ("Knopp") announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation to KNS-760704 for the treatment of amyotrophic lateral sclerosis (ALS).

(Logo: http://www.newscom.com/cgi-bin/prnh/20070924/KNOPPLOGO )

KNS-760704 is now completing Phase 1 studies to evaluate the safety, tolerability and pharmacokinetics of the compound in healthy human subjects. Knopp expects to initiate Phase 2 studies in ALS patients in the first quarter of 2008.

"Congress passed the Orphan Drug Act because it recognized that adequate drugs for many rare diseases have not been developed," said Michael Bozik, M.D., president and CEO of Knopp. "The designation of KNS-760704 as an orphan drug underscores the importance of developing effective treatments for patients with ALS."

About KNS-760704

KNS-760704 is an orally administered small molecule in clinical development by Knopp for the treatment of amyotrophic lateral sclerosis (ALS). The drug is an optical enantiomer of a selective, high affinity dopamine agonist marketed in other neurological indications. Both KNS-760704 and the marketed agonist demonstrate neuroprotective properties independent of dopamine receptor activity, but KNS-760704 exhibits greatly reduced dopamine receptor affinity. This makes it possible to clinically evaluate the potential neuroprotective activity of KNS-760704 over a broad dose range.

About ALS

Amyotrophic lateral sclerosis (ALS), often called Lou Gehrig's disease, is a rapid, universally fatal neurodegenerative disorder characterized by progressive muscle weakness and wasting. ALS affects adults in the prime of life and creates a substantial burden for caregivers. U.S. prevalence is nearly 30,000 and the incidence is 1.2 per 100,000. Only a single drug has b
'/>"/>

SOURCE Knopp Neurosciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
2. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
3. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
4. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
5. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
6. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
7. AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II Study with Novel Cystic Fibrosis Therapy
8. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
9. Point of Care Strep Tests Speed Treatment, Lower Costs
10. Rapid HIV Testing Increases Possibility of Treatment
11. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Lilly and Company (NYSE: LLY ) announced today the ... up to $1.6 billion aggregate principal amount of certain of ... tendered, and did not validly withdraw, their notes on or ... time, on May 27, 2015 (the early tender date), and ... receive the total consideration. The total consideration for each series ...
(Date:5/28/2015)... and HOUSTON , May 28, 2015 ... EPI) today reported financial results for the second quarter and ... specified otherwise, are expressed in Canadian dollars and in accordance ... Results ESSA recorded a net loss of ... ended March 31, 2015 (Q2-2015), compared to a net loss ...
(Date:5/28/2015)... Research and Markets ( ... Jain PharmaBiotech,s new report  "RNAi - Technologies, ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... the use of double stranded RNA (dsRNA). ... processed into short 21-23 nucleotide RNAs termed ...
Breaking Medicine Technology:Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3
... ( www.curemark.com ), a drug research and development company focused ... & Renshaw Annual Global Investment Conference held September 12-15 in ... 5,000 investors and other attendees.   "Curemark was ... present at the conference, which included a full roster of ...
... OmniComm Systems, Inc. (OTC Bulletin Board: ... and services announced that it will be hosting the ... Beach Resort in Fort Lauderdale, Florida from November 03-05, ... from participating Life Science organizations. The informal ambiance provides ...
Cached Medicine Technology:Curemark Presents at the Rodman & Renshaw Annual Global Investment Conference 2OmniComm Systems, Inc. Hosts Autumn 2010 eClinical Forum Meeting 2OmniComm Systems, Inc. Hosts Autumn 2010 eClinical Forum Meeting 3
(Date:5/29/2015)... (PRWEB) May 29, 2015 Mediaplanet has ... “beauty of protection”. Skin Health is a cross-platform ... within the markets of New York, Los Angeles, and ... 750,000 readers. Its digital counterpart will reach a national ... To read more the Skin Health campaign and Colorescience, ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Healthpointe ... consultations with specialists, physical therapy, and injections , ... mid back and/or lower back pain, Healthpointe has ... injections for herniated discs, disc protrusions and other ... , Healthpointe’s team of renowned surgeons are ...
(Date:5/29/2015)... Dr. Rodger Murphree, author of Treating ... now offering free weekly call in teleconferences each ... to reduce symptoms associated with fibromyalgia including chronic ... fog. , To find out more about ... in teleconferences simply go to http://www.endfibronow.com ...
(Date:5/29/2015)... May 29, 2015 Healthpointe’s electromyography ... to the Los Angeles County clinics including its ... are now being offered at all Healthpointe locations ... and San Bernardino County. , As the ... send electrical impulses throughout the body and ...
(Date:5/29/2015)... 2015 This is a professional ... the Naproxen industry.The report provides a basic overview ... industry chain structure. The Naproxen market ... development trends, competitive landscape analysis, and key regions ... well as manufacturing processes and cost structures are ...
Breaking Medicine News(10 mins):Health News:Mediaplanet Launches “Skin Health” Campaign Featuring Colorescience 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 3Health News:Healthpointe Is Now Offering EMG and NCV Diagnostics at All Clinics throughout Southern California. 2Health News:Naproxen Market Analysis For Global & China Regions 2020 Research Forecasts 2
... (MGH) researchers have identified a new molecular pathway that ... This early-stage kidney disease affects 100 million people around ... the kidneys filtering structures. Blocking this pathway could ... slow the process of kidney failure. The research ...
... impact on behavior, studies show , , WEDNESDAY, Dec. 19 (HealthDay ... trillion cells, looking for perhaps only one or a handful ... of new studies says. , The research, conducted with rodents ... , could rewrite the textbooks on just how important individual ...
... a way to use a firefly gene to let them ... against some forms of cancer and its serious complication. ... and leukemia, a form of cancer where it is particularly ... prognosis is generally poor. There is now no widely effective ...
... Helping Latino Nonprofits and Families With Cash,Donation. Photo ... Latino with,HIV., WASHINGTON, Dec. 19 The ... This holiday season, MAYA is giving $10,000 to ... the Latino community.,MAYA will also donate cash to ...
... Health Net of California See Big Increases in ... Surveyor from HealthLeaders-InterStudy Reveals ... NASHVILLE, Tenn., Dec. 19 HealthLeaders-InterStudy, the,leading ... managed,care enrollment from January 2007 to July 2007 ...
... volunteer John,Cleland has run four marathons, but the race ... Diagnosed with the disease as a college,undergraduate, Cleland underwent ... punishing rounds of chemotherapy followed. But when,Cleland,s cancer spread ... Then Cleland,s doctor offered one small ray of ...
Cached Medicine News:Health News:Receptor protein appears to be key in breakdown of kidney filtration 2Health News:Receptor protein appears to be key in breakdown of kidney filtration 3Health News:Brain Cells More Powerful Than You Think 2Health News:Brain Cells More Powerful Than You Think 3Health News:Brain Cells More Powerful Than You Think 4Health News:Firefly genes allow testing of new therapy against lymphoma 2Health News:Firefly genes allow testing of new therapy against lymphoma 3Health News:HIV/AIDS Rate Increases in DC Area Latino Population, Community Lacks Resources 2Health News:Boosts in Managed Care Enrollment Seen Across The Board 2Health News:Boosts in Managed Care Enrollment Seen Across The Board 3Health News:New Book Looks at Clinical Research from the Patient's Point of View 2Health News:New Book Looks at Clinical Research from the Patient's Point of View 3
... vascular tests for assessing peripheral vascular disease. With the Portable ABI Kit, you get the basic equipment ... ... ... The ankle-arm pressure index (also known as the Ankle/Brachial ...
... Clinitek Microalbumin Strips provide albumin, creatinine ... The Clinitek Microalbumin product is useful to ... or hypertension in order to detect early ... elevation of the urinary albumin excretion rate, ...
... today's busy physician's office environment, ... contribute to timing errors and ... strips are read visually. Studies ... is performed with an instrument, ...
... Ultra device consists of a non-compliant balloon ... mounted longitudinally on its outer surface. When ... the atherotomes score the plaque, creating initiation ... to as Atherotomy, allows dilatation of the ...
Medicine Products: